在阿尔茨海默氏病中皮层厚度增加
Tony X Phan1, Sheena Baratono2, William Drew2
1Department of Neurology, Vanderbilt University Medical Center, Nashville, TN.
Annals of neurology
|February 24, 2024
概括
在阿尔茨海默氏症 (AD) 中,前带皮层 (ACC) 等特定大脑区域的皮层厚度增加与保存的认知有关,并可能抵消相关区域的缩.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 阿尔茨海默氏症 (AD) 的特点是大脑缩的广泛扩散.
- 一些大脑区域,包括前带状皮质 (ACC),可能会显示AD患者的厚度增加,与对照组相比.
- 这种皮层厚度增加的临床意义和潜在机制尚不清楚.
研究的目的:
- 调查在散发性阿尔茨海默病 (AD) 中皮质厚度增加的发生和临床相关性.
- 为了确定AD中皮质厚度的增加是否与特定的临床症状有关.
- 探索皮层厚度增加区域与大脑缩区域之间的关系.
主要方法:
- 来自阿尔茨海默病神经成像计划 (ADNI) 的临床,神经心理和神经成像数据的横截面分析.
- 在AD受试者和健康对照者之间对皮层厚度的比较.
- 应用缩网络映射来确定增加厚度和缩区域之间的功能连接.
主要成果:
- 阿尔茨海默病患者在前带皮质 (ACC) 和视觉皮质的皮质厚度增加.
- 左侧ACC增加的厚度与保持认知功能相关.
- 左视觉皮层增加的厚度与幻觉的发生有关.
- 增加厚度的区域在功能上与大脑缩区域相连,但与大脑缩区域有反相关性 (r = -0.81,p < 0.05).
结论:
- 在AD中皮质厚度增加在临床上是相关的,并与症状相关.
- 这种现象主要发生在与缩区域功能相关但与其有反相关的脑部区域.
- 研究结果表明,在应对阿尔茨海默氏症中神经退行症时,可能存在补偿性神经可塑性机制.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.3K
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
